\-\ Texto\\:\\ \ \(0\)\
\-\ labs\\ were\\ normal\\ except\\ for\\ a\\ small\\ amount\\ of\\ blood\\ in\\ the\\ urine\ \(0\)\
\-\ although\\ intervention\\ with\\ angioplasty\\ was\\ considered\\,\\ it\\ was\\ felt\\ that\\ the\\ risk\\ for\\ further\\ renal\\ injury\\ outweighed\\ any\\ immediate\\ benefits\\ of\\ pta\\,\\ given\\ that\\ hypertension\\ is\\ currently\\ controlled\\ with\\ 2\\ medications\\.\\ he\\ will\\ continue\\ on\\ plavix\\ indefinitely\\ to\\ prevent\\ recurrence\\ of\\ renal\\ infarction\\.\\ should\\ the\\ patient\\ become\\ symptomatic\\ again\\ \\(either\\ infarct\\ or\\ hypertension\\)\\,\\ percutaneous\\ intervention\\ will\\ be\\ reconsidered\\.\ \(0\)\
\-\ ct\\ kub\\ was\\ performed\\ to\\ evaluate\\ for\\ suspected\\ renal\\ stones\\.\\ ct\\ evaluation\\ demonstrated\\ normal\\ appearing\\ kidneys\\,\\ with\\ no\\ evidence\\ of\\ renal\\ obstruction\\ or\\ urolithiasis\\.\\ a\\ recently\\ passed\\ stone\\ was\\ considered\\,\\ and\\ the\\ patient\\ discharged\\ home\\.\ \(0\)\
\-\ the\\ patient\\ returned\\ 4\\ days\\ later\\ with\\ continued\\ and\\ worsening\\ left\\ flank\\ pain\\.\\ there\\ was\\ flank\\ tenderness\\ on\\ physical\\ exam\\.\\ ua\\ showed\\ moderate\\ blood\\.\\ cbc\\ was\\ normal\\,\\ including\\ a\\ normal\\ white\\ count\\.\\ ct\\ kub\\ was\\ again\\ performed\\.\\ there\\ was\\ no\\ urolithiasis\\ or\\ hydronephrosis\\,\\ but\\ there\\ was\\ interval\\ development\\ of\\ significant\\ perinephric\\ stranding\\.\\ given\\ lack\\ of\\ other\\ clinical\\ findings\\ of\\ pyelonephritis\\,\\ a\\ renal\\ mass\\ could\\ not\\ be\\ excluded\\,\\ and\\ a\\ contrast\\ examination\\ was\\ ordered\\.\ \(0\)\
\-\ contrast\\ ct\\ demonstrated\\ a\\ wedge\\ shaped\\ area\\ of\\ non\\-perfusion\\ in\\ the\\ upper\\ outer\\ aspect\\ of\\ the\\ left\\ kidney\\.\\ a\\ renal\\ infarct\\ was\\ felt\\ to\\ be\\ the\\ most\\ likely\\ etiology\\,\\ though\\ there\\ was\\ no\\ history\\ to\\ suggest\\ a\\ source\\.\\ further\\ evaluation\\ included\\ echocardiography\\,\\ which\\ was\\ negative\\.\\ laboratory\\ analysis\\ for\\ abnormal\\ clotting\\ factors\\ was\\ negative\\.\\ as\\ fibromuscular\\ dysplasia\\ and\\ vasculitis\\ were\\ also\\ considered\\,\\ renal\\ mra\\ performed\\.\\ this\\ again\\ demonstrated\\ the\\ area\\ of\\ non\\-perfusion\\ in\\ the\\ left\\ kidney\\,\\ but\\ also\\ showed\\ irregular\\ narrowing\\ and\\ dilation\\ of\\ both\\ renal\\ arteries\\,\\ highly\\ suggest\\ of\\ fibromuscular\\ dysplasia\\.\ \(0\)\
\-\ the\\ patient\\ was\\ treated\\ for\\ symptoms\\ and\\ placed\\ on\\ plavix\\.\\ outpatient\\ angiography\\ was\\ then\\ performed\\,\\ confirming\\ findings\\ of\\ fmd\\ previously\\ seen\\ on\\ mr\ \(0\)\
\-\ fibromuscular\\ dysplasia\\,\\ renal\\ infarct\ \(0\)\
\-\ initial\\ appearance\\ of\\ the\\ kidney\\:\ \(0\)\
\-\ pyelonephritis\ \(60\)\
\-\ renal\\ infarct\ \(6\)\
\-\ renal\\ neoplasm\\ \\(rcc\\,\\ aml\\)\\,\\ possibly\\ with\\ acute\\ hemorrhage\ \(0\)\
\-\ for\\ renal\\ artery\\ changes\\:\ \(0\)\
\-\ atherosclerotic\\ disease\ \(11\)\
\-\ fibromuscular\\ dysplasia\ \(11\)\
\-\ vasculitis\ \(67\)\
\-\ trauma\ \(1087\)\
\-\ 38\\ year\\ old\\ healthy\\ male\\ with\\ past\\ medical\\ history\\ significant\\ only\\ for\\ recent\\ onset\\ hypertension\\.\\ presented\\ to\\ the\\ emergency\\ department\\ with\\ acute\\ onset\\ of\\ left\\ flank\\ pain\\.\ \(0\)\
\-\ this\\ patient\\â\\€\\™s\\ demographics\\ and\\ presentation\\ where\\ somewhat\\ atypically\\,\\ but\\ demonstrate\\ the\\ need\\ for\\ proper\\ differential\\ diagnoses\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ renal\\:\\ 0\\.07406179469590585\ \(0\)\
\-\ fibromuscular\\:\\ 0\\.05343674890331746\ \(0\)\
\-\ non\\-perfusion\\:\\ 0\\.04238230011522355\ \(0\)\
\-\ was\\:\\ 0\\.03801067393129565\ \(0\)\
\-\ infarct\\:\\ 0\\.036458056760771365\ \(0\)\
\-\ urolithiasis\\:\\ 0\\.03302696286014993\ \(0\)\
\-\ dysplasia\\:\\ 0\\.03243366070619908\ \(0\)\
\-\ plavix\\:\\ 0\\.030853957457539077\ \(0\)\
\-\ again\\:\\ 0\\.029610491990294457\ \(0\)\
\-\ flank\\:\\ 0\\.028988422199781903\ \(0\)\
\-\ kub\\:\\ 0\\.02690693557258797\ \(0\)\
\-\ considered\\:\\ 0\\.02487650775681236\ \(0\)\
\-\ hypertension\\:\\ 0\\.02429409412716482\ \(0\)\
\-\ pyelonephritis\\:\\ 0\\.023975370324410595\ \(0\)\
\-\ performed\\:\\ 0\\.022909407031031916\ \(0\)\
\-\ kidney\\:\\ 0\\.021709496070072186\ \(0\)\
\-\ vasculitis\\:\\ 0\\.02102339984363549\ \(0\)\
\-\ reconsidered\\:\\ 0\\.019524930873573446\ \(0\)\
\-\ felt\\:\\ 0\\.0193256147998546\ \(0\)\
\-\ atypically\\:\\ 0\\.01855025513292882\ \(0\)\
\-\ intervention\\:\\ 0\\.018292707355145398\ \(0\)\
\-\ demonstrated\\:\\ 0\\.018082355642718515\ \(0\)\
\-\ indefinitely\\:\\ 0\\.017858711689535116\ \(0\)\
\-\ suggest\\:\\ 0\\.017496964862464756\ \(0\)\
\-\ outweighed\\:\\ 0\\.01732230892195288\ \(0\)\
\-\ fmd\\:\\ 0\\.016192492505496786\ \(0\)\
\-\ pta\\:\\ 0\\.015426978728769539\ \(0\)\
\-\ clotting\\:\\ 0\\.015025406409867695\ \(0\)\
\-\ demographics\\:\\ 0\\.014847262246036634\ \(0\)\
\-\ aml\\:\\ 0\\.014243141024207534\ \(0\)\
\-\ given\\:\\ 0\\.014083723040943956\ \(0\)\
\-\ for\\:\\ 0\\.014021310550821446\ \(0\)\
\-\ rcc\\:\\ 0\\.013872586505392007\ \(0\)\
\-\ benefits\\:\\ 0\\.013551597580813828\ \(0\)\
\-\ showed\\:\\ 0\\.013470208018863927\ \(0\)\
\-\ angioplasty\\:\\ 0\\.013181043061998304\ \(0\)\
\-\ but\\:\\ 0\\.013143052651684166\ \(0\)\
\-\ wedge\\:\\ 0\\.013096688927836596\ \(0\)\
\-\ echocardiography\\:\\ 0\\.013096688927836596\ \(0\)\
\-\ further\\:\\ 0\\.013064635297116626\ \(0\)\
\-\ perinephric\\:\\ 0\\.013015194813231592\ \(0\)\
\-\ confirming\\:\\ 0\\.013015194813231592\ \(0\)\
\-\ area\\:\\ 0\\.012989597327568592\ \(0\)\
\-\ onset\\:\\ 0\\.0129683712784863\ \(0\)\
\-\ normal\\:\\ 0\\.012880888986529818\ \(0\)\
\-\ will\\:\\ 0\\.012853274126822798\ \(0\)\
\-\ proper\\:\\ 0\\.012644640294416068\ \(0\)\
\-\ passed\\:\\ 0\\.01238451148518474\ \(0\)\
\-\ \\,\\:\\ 0\\.01236416164622226\ \(0\)\
\-\ controlled\\:\\ 0\\.01232365136983789\ \(0\)\
\-\ atherosclerotic\\:\\ 0\\.01232365136983789\ \(0\)\
\-\ negative\\:\\ 0\\.012269808468148435\ \(0\)\
\-\ there\\:\\ 0\\.012228034196778738\ \(0\)\
\-\ diagnoses\\:\\ 0\\.012149803625656095\ \(0\)\
\-\ evaluation\\:\\ 0\\.011933840364551961\ \(0\)\
\-\ outpatient\\:\\ 0\\.011692968041791036\ \(0\)\
\-\ mra\\:\\ 0\\.011514823877959974\ \(0\)\
\-\ ct\\:\\ 0\\.011493304359538875\ \(0\)\
\-\ blood\\:\\ 0\\.011213514771679325\ \(0\)\
\-\ excluded\\:\\ 0\\.01111986462004825\ \(0\)\
\-\ continue\\:\\ 0\\.011083715876383493\ \(0\)\
\-\ significant\\:\\ 0\\.011047342072376074\ \(0\)\
\-\ 38\\:\\ 0\\.010944323430108613\ \(0\)\
\-\ ua\\:\\ 0\\.010910702656130873\ \(0\)\
\-\ outer\\:\\ 0\\.010910702656130873\ \(0\)\
\-\ percutaneous\\:\\ 0\\.010877545631774297\ \(0\)\
\-\ source\\:\\ 0\\.010844839737409443\ \(0\)\
\-\ immediate\\:\\ 0\\.010749310101232727\ \(0\)\
\-\ stones\\:\\ 0\\.010568937058100723\ \(0\)\
\-\ returned\\:\\ 0\\.010511699921817745\ \(0\)\
\-\ possibly\\:\\ 0\\.010511699921817745\ \(0\)\
\-\ shaped\\:\\ 0\\.010455794003153641\ \(0\)\
\-\ analysis\\:\\ 0\\.010455794003153641\ \(0\)\
\-\ except\\:\\ 0\\.01040115878421721\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.010347737782330887\ \(0\)\
\-\ angiography\\:\\ 0\\.010321465978166966\ \(0\)\
\-\ patient\\:\\ 0\\.010295576092745048\ \(0\)\
\-\ need\\:\\ 0\\.010244330606648937\ \(0\)\
\-\ stone\\:\\ 0\\.01021915921273717\ \(0\)\
\-\ prevent\\:\\ 0\\.010194248666978644\ \(0\)\
\-\ acute\\:\\ 0\\.010143650620704305\ \(0\)\
\-\ somewhat\\:\\ 0\\.01009711035366644\ \(0\)\
\-\ interval\\:\\ 0\\.010073426948755354\ \(0\)\
\-\ stranding\\:\\ 0\\.009936026915486246\ \(0\)\
\-\ urine\\:\\ 0\\.009913871494560949\ \(0\)\
\-\ highly\\:\\ 0\\.009891918409072312\ \(0\)\
\-\ become\\:\\ 0\\.009785063210584732\ \(0\)\
\-\ home\\:\\ 0\\.009764250559759938\ \(0\)\
\-\ dilation\\:\\ 0\\.009682756445154934\ \(0\)\
\-\ ordered\\:\\ 0\\.0096628073999273\ \(0\)\
\-\ recently\\:\\ 0\\.00958462665063509\ \(0\)\
\-\ though\\:\\ 0\\.009527615769343464\ \(0\)\
\-\ be\\:\\ 0\\.009503053293345644\ \(0\)\
\-\ included\\:\\ 0\\.009471925722993622\ \(0\)\
\-\ kidneys\\:\\ 0\\.009453645436009923\ \(0\)\
\-\ discharged\\:\\ 0\\.009417496692345161\ \(0\)\
\-\ lack\\:\\ 0\\.009346790237522341\ \(0\)\
\-\ were\\:\\ 0\\.009328299695624622\ \(0\)\
\-\ healthy\\:\\ 0\\.00926123508102546\ \(0\)\
\-\ factors\\:\\ 0\\.009227847792177701\ \(0\)\
\-\ department\\:\\ 0\\.009211326447735967\ \(0\)\
\-\ contrast\\:\\ 0\\.009196036955807238\ \(0\)\
\-\ left\\:\\ 0\\.00919331989685495\ \(0\)\
\-\ cbc\\:\\ 0\\.009178620553371115\ \(0\)\
\-\ medications\\:\\ 0\\.009162432976012113\ \(0\)\
\-\ appearing\\:\\ 0\\.00913038121911436\ \(0\)\
\-\ recurrence\\:\\ 0\\.008961351174841621\ \(0\)\
\-\ either\\:\\ 0\\.008946558228749365\ \(0\)\
\-\ development\\:\\ 0\\.008946558228749365\ \(0\)\
\-\ count\\:\\ 0\\.008931855759957452\ \(0\)\
\-\ suspected\\:\\ 0\\.008845480737779415\ \(0\)\
\-\ continued\\:\\ 0\\.008845480737779415\ \(0\)\
\-\ findings\\:\\ 0\\.008744408345144037\ \(0\)\
\-\ etiology\\:\\ 0\\.00869476296322277\ \(0\)\
\-\ previously\\:\\ 0\\.008629259015031965\ \(0\)\
\-\ amount\\:\\ 0\\.008578111422610607\ \(0\)\
\-\ arteries\\:\\ 0\\.008503374434461494\ \(0\)\
\-\ infarction\\:\\ 0\\.008395452992375216\ \(0\)\
\-\ where\\:\\ 0\\.008383755421098359\ \(0\)\
\-\ placed\\:\\ 0\\.00831474074349636\ \(0\)\
\-\ evaluate\\:\\ 0\\.008303428505425656\ \(0\)\
\-\ narrowing\\:\\ 0\\.00823665070709134\ \(0\)\
\-\ irregular\\:\\ 0\\.008193140991601873\ \(0\)\
\-\ symptomatic\\:\\ 0\\.008161017847822626\ \(0\)\
\-\ currently\\:\\ 0\\.008139838449548215\ \(0\)\
\-\ also\\:\\ 0\\.008099132661875728\ \(0\)\
\-\ worsening\\:\\ 0\\.00808769223654038\ \(0\)\
\-\ moderate\\:\\ 0\\.008077397376463454\ \(0\)\
\-\ emergency\\:\\ 0\\.007778337975914125\ \(0\)\
\-\ a\\:\\ 0\\.007626919265742333\ \(0\)\
\-\ could\\:\\ 0\\.007578264288054213\ \(0\)\
\-\ laboratory\\:\\ 0\\.007569932057341505\ \(0\)\
\-\ risk\\:\\ 0\\.007440400594613189\ \(0\)\
\-\ later\\:\\ 0\\.007416871733156067\ \(0\)\
\-\ including\\:\\ 0\\.007416871733156067\ \(0\)\
\-\ then\\:\\ 0\\.007310016534668486\ \(0\)\
\-\ obstruction\\:\\ 0\\.007243750116801528\ \(0\)\
\-\ or\\:\\ 0\\.007222519824257506\ \(0\)\
\-\ labs\\:\\ 0\\.007144168285901775\ \(0\)\
\-\ that\\:\\ 0\\.0070960611949943435\ \(0\)\
\-\ presentation\\:\\ 0\\.007075482294449717\ \(0\)\
\-\ neoplasm\\:\\ 0\\.006995568692095982\ \(0\)\
\-\ on\\:\\ 0\\.006960490503513732\ \(0\)\
\-\ although\\:\\ 0\\.006937330001386067\ \(0\)\
\-\ recent\\:\\ 0\\.0069055746366341285\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.006837155250423163\ \(0\)\
\-\ white\\:\\ 0\\.006812750511326966\ \(0\)\
\-\ initial\\:\\ 0\\.0068066878444214135\ \(0\)\
\-\ injury\\:\\ 0\\.006548578225694231\ \(0\)\
\-\ should\\:\\ 0\\.006548578225694231\ \(0\)\
\-\ mr\\:\\ 0\\.006526921807563544\ \(0\)\
\-\ past\\:\\ 0\\.006526921807563544\ \(0\)\
\-\ differential\\:\\ 0\\.006521538051329158\ \(0\)\
\-\ any\\:\\ 0\\.006468353444885322\ \(0\)\
\-\ aspect\\:\\ 0\\.006452624842508071\ \(0\)\
\-\ examination\\:\\ 0\\.0063856322968138595\ \(0\)\
\-\ clinical\\:\\ 0\\.006320456250158664\ \(0\)\
\-\ medical\\:\\ 0\\.006320456250158664\ \(0\)\
\-\ days\\:\\ 0\\.006295851673490331\ \(0\)\
\-\ tenderness\\:\\ 0\\.006247385391542388\ \(0\)\
\-\ no\\:\\ 0\\.0062051260868062645\ \(0\)\
\-\ only\\:\\ 0\\.00617647033289648\ \(0\)\
\-\ treated\\:\\ 0\\.006148679894432354\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.006139487354916962\ \(0\)\
\-\ artery\\:\\ 0\\.006116658634875478\ \(0\)\
\-\ s\\:\\ 0\\.005891268430563912\ \(0\)\
\-\ changes\\:\\ 0\\.0058871345582573575\ \(0\)\
\-\ appearance\\:\\ 0\\.005874775424842889\ \(0\)\
\-\ abnormal\\:\\ 0\\.005858394808449306\ \(0\)\
\-\ likely\\:\\ 0\\.005793966264268405\ \(0\)\
\-\ he\\:\\ 0\\.005731219572194759\ \(0\)\
\-\ 4\\:\\ 0\\.005723490156680397\ \(0\)\
\-\ history\\:\\ 0\\.005674108354360978\ \(0\)\
\-\ trauma\\:\\ 0\\.005617809571533483\ \(0\)\
\-\ presented\\:\\ 0\\.0055994173918807915\ \(0\)\
\-\ \\:\\:\\ 0\\.005434013538416659\ \(0\)\
\-\ evidence\\:\\ 0\\.00538567928693961\ \(0\)\
\-\ both\\:\\ 0\\.005245673054533946\ \(0\)\
\-\ to\\:\\ 0\\.005133030149555124\ \(0\)\
\-\ symptoms\\:\\ 0\\.005119368934851296\ \(0\)\
\-\ physical\\:\\ 0\\.005039676128801054\ \(0\)\
\-\ pain\\:\\ 0\\.005017346959282379\ \(0\)\
\-\ upper\\:\\ 0\\.004956924291751727\ \(0\)\
\-\ most\\:\\ 0\\.004742392167615568\ \(0\)\
\-\ other\\:\\ 0\\.004734708049765501\ \(0\)\
\-\ small\\:\\ 0\\.004732152125916151\ \(0\)\
\-\ demonstrate\\:\\ 0\\.004727048416665963\ \(0\)\
\-\ the\\:\\ 0\\.004652620158295099\ \(0\)\
\-\ this\\:\\ 0\\.004620851987087178\ \(0\)\
\-\ it\\:\\ 0\\.00461742400128129\ \(0\)\
\-\ exam\\:\\ 0\\.0045125815864171595\ \(0\)\
\-\ 2\\:\\ 0\\.00442332811661189\ \(0\)\
\-\ of\\:\\ 0\\.004200858201850544\ \(0\)\
\-\ seen\\:\\ 0\\.004059200997758871\ \(0\)\
\-\ which\\:\\ 0\\.0038344821808715115\ \(0\)\
\-\ male\\:\\ 0\\.0037144363891525797\ \(0\)\
\-\ \\(\\:\\ 0\\.003472892914633945\ \(0\)\
\-\ \\)\\:\\ 0\\.003430469673621659\ \(0\)\
\-\ disease\\:\\ 0\\.0033575421663839043\ \(0\)\
\-\ as\\:\\ 0\\.0031071574660916537\ \(0\)\
\-\ in\\:\\ 0\\.0030389223327422234\ \(0\)\
\-\ and\\:\\ 0\\.003028997692609445\ \(0\)\
\-\ not\\:\\ 0\\.002968314114764268\ \(0\)\
\-\ mass\\:\\ 0\\.00285687742054703\ \(0\)\
\-\ year\\:\\ 0\\.0022983299742137375\ \(0\)\
\-\ old\\:\\ 0\\.002103208165534266\ \(0\)\
\-\ with\\:\\ 0\\.0019688202707433366\ \(0\)\
\-\ \\.\\:\\ 0\\.0019627147361513564\ \(0\)\
\-\ is\\:\\ 0\\.0013516605249632829\ \(0\)\
